Topic: non-small cell lung cancer
AZ put skeptics to rest with a long-promised "return to growth." But it’s still far from its $40B sales goal—and its CEO doubled down on it anyway.
In June, Merck upstaged Roche with squamous non-small cell lung cancer data. And thanks to a new nod, it looks like it’ll beat Roche to market, too.
Seventeen cancer drugs from global and local drugmakers take an average 56.7% discount to win spots on China's insurance scheme.
It’s been a long road for Pfizer’s dacomitinib, but the targeted lung cancer drug finally has an FDA green light.
U.S. medtech exports to China are targets in trade war; Alunbrig beats Xalkori in 1st-line lung cancer; FDA blasts Huahai for careless process changes.
AstraZeneca already has an Imfinzi OK in lung cancer maintenance. But new survival data will strengthen its case—and its lead over its I-O rivals.
Pfizer’s about to get even more competition in ALK-positive lung cancer. And if new data are any indication, it’s pretty stiff.
Roche has been chomping at the bit to challenge Merck in previously untreated lung cancer, but it’s going to have to wait a little longer.
Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market.
Excluding ALK and EGFR, about two-thirds of new NSCLC patients are now starting their treatment with Keytruda, said an executive.